about
Response to imatinib plus sirolimus in advanced chordoma.Sacral Chordoma: Long-term Outcome of a Large Series of Patients Surgically Treated at Two Reference Centers.Best practices for the management of local-regional recurrent chordoma: a position paper by the Chordoma Global Consensus Group.Steroid premedication markedly reduces liver and bone marrow toxicity of trabectedin in advanced sarcoma.Sunitinib malate and figitumumab in solitary fibrous tumor: patterns and molecular bases of tumor response.High-grade sarcomatous overgrowth in solitary fibrous tumors: a clinicopathologic study of 10 cases.Adaptive immune contexture at the tumour site and downmodulation of circulating myeloid-derived suppressor cells in the response of solitary fibrous tumour patients to anti-angiogenic therapyResectable extra-pleural and extra-meningeal solitary fibrous tumours: A multi-centre prognostic study.Sunitinib-induced morpho-functional changes and drug effectiveness in malignant solitary fibrous tumoursHistotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial.Sporadic extra abdominal wall desmoid-type fibromatosis: surgical resection can be safely limited to a minority of patients.Myxoid/round cell and pleomorphic liposarcomas: prognostic factors and survival in a series of patients treated at a single institution.Preoperative imatinib mesylate for unresectable or locally advanced primary gastrointestinal stromal tumors (GIST).Response to sunitinib malate in advanced alveolar soft part sarcoma.Alveolar soft part sarcoma: clinical presentation, treatment, and outcome in a series of 33 patients at a single institution.Receptor tyrosine kinase pathway analysis sheds light on similarities between clear-cell sarcoma and metastatic melanoma.Emerging therapies for adult soft tissue sarcoma.Melan-A/MART-1 immunity in a EWS-ATF1 translocated clear cell sarcoma patient treated with sunitinib: a case reportResponse of conventional chondrosarcoma to gemcitabine alone: a case reportSystemic treatment in advanced soft tissue sarcoma: what is standard, what is new.Extraskeletal myxoid chondrosarcoma: tumor response to sunitinib.Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study.Anthracycline-based chemotherapy in extraskeletal myxoid chondrosarcoma: a retrospective studyHow a Clinical Trial Unit can improve independent clinical research in rare tumors: the Italian Sarcoma Group experience.Targeted therapies in rare sarcomas: IMT, ASPS, SFT, PEComa, and CCS.Short, full-dose adjuvant chemotherapy (CT) in high-risk adult soft tissue sarcomas (STS): long-term follow-up of a randomized clinical trial from the Italian Sarcoma Group and the Spanish Sarcoma Group.Establishment and genomic characterization of the new chordoma cell line Chor-IN-1.Medical treatment of advanced chordomas.Activity of Pazopanib and Trabectedin in Advanced Alveolar Soft Part Sarcoma.Review of past and present clinical cases with a view to future treatment options.(Neo)adjuvant treatment in localised soft tissue sarcoma: The unsolved affair.The safety and efficacy of trabectedin for the treatment of liposarcoma or leiomyosarcoma.Long-term Efficacy of Methotrexate Plus Vinblastine/Vinorelbine in a Large Series of Patients Affected by Desmoid-Type Fibromatosis.Sirolimus in Advanced Epithelioid Hemangioendothelioma: A Retrospective Case-Series Analysis from the Italian Rare Cancer Network Database.Solitary fibrous tumour presenting with a single bone metastasis: report of six cases and literature review.Pharmacological therapies for Liposarcoma.Hormonal manipulation with toremifene in sporadic desmoid-type fibromatosis.Pazopanib in advanced vascular sarcomas: an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) retrospective analysis.Neoadjuvant treatment: a novel standard?Adaptive Immunity in Fibrosarcomatous Dermatofibrosarcoma Protuberans and Response to Imatinib Treatment.
P50
Q33273440-7688B4B6-7B05-45BC-85FA-60899BF58B8BQ33275974-9C1E6F14-4045-440E-99BA-EAF913BFCB26Q33276384-E09E149C-723B-4E75-A786-DA407C6517C8Q33371397-C562356A-6B40-441F-A90D-D46082EB9C31Q33389496-7637EE27-271D-4125-9AE4-8E644C82A7A7Q33401339-94C48F15-6B2A-49E0-AF2D-097FCFF331E3Q33416940-186A645A-0344-446F-8462-80ACFA550031Q33430341-CEA3742D-EA25-4F8A-A2F1-EAC605C1D244Q33433105-197C9932-0A31-464F-9F9C-F1D8961F09DCQ33441802-DC4620CB-D84F-4CEF-A564-CB19E3274E41Q34042707-12B285A6-A345-46A7-A94E-572F7540BDF4Q34579626-329BA91C-0EEF-4194-9D3B-F1850D8D4BC5Q34602457-79E38554-788F-4D30-BBF6-3ABAF84FEB41Q34603983-C7B22D03-E1F8-4832-91C1-E7C0F0825FA4Q34621104-32824699-FC27-45F2-9F23-8D84D0029829Q34633416-E54A2DB1-2119-4D39-824F-187A3918015DQ34659806-67F25D35-D043-4E96-8AC1-637F4682594CQ34669336-42CA8A68-75A7-4AB1-B10D-8DA7B21FB939Q35194125-620717B7-C568-4BAF-B0AE-21BF84563B54Q36389964-41B292B4-1581-46B9-8D95-01554ADAE5FBQ36499849-95E6A1BA-101C-44DC-86C9-3B45FDD893C4Q36856816-1771AA66-5BE1-41E6-99EF-8832B2914653Q37427998-E6081C11-B2B7-451B-891E-20C8C74C1BEEQ37671153-D85DED24-2A5E-4CE3-A06F-741AE0CC5FA8Q38149146-ABBA2014-9D1A-4A30-8603-6BA6B7E0B77DQ38386665-2058D84C-248C-414A-87A6-6CE8281D733BQ38611099-28EFC07A-B479-49EA-A648-AC254D69DE82Q38650912-0BCC0834-F77C-4064-B2BB-0A98F1AA8E0EQ38654374-CE2925AE-F9E0-4862-AB85-2646935FFA95Q38688923-3D82211B-7B17-4371-9769-C974A524C072Q38793215-FF959B29-48AA-46E7-A04A-38F1788AC75DQ38797843-F45FB984-41E0-489B-B558-751EA0E0E112Q38836706-CF9686F2-29E4-4C29-BAD9-69A8A4F2F9A3Q38873696-8F051F59-95C8-4E45-B826-768CDB92913FQ38944688-2D306DD6-EE8C-4BCB-B815-7A3DF2A275FFQ38991731-08A3E02D-FF98-4B3B-AC76-3F69517B43E7Q39180339-52CCFDD9-6E55-4B39-9A57-7342668B43E3Q39191957-1A0EA056-355D-4E47-B7A3-AF414050FDCBQ39252219-7C547AAD-21BB-4B90-920D-5FFF44F076AFQ39409643-788D699A-4DD9-4CF1-B4DB-FC1287B9D533
P50
description
hulumtuese
@sq
researcher
@en
հետազոտող
@hy
name
Silvia Stacchiotti
@ast
Silvia Stacchiotti
@en
Silvia Stacchiotti
@es
Silvia Stacchiotti
@nl
type
label
Silvia Stacchiotti
@ast
Silvia Stacchiotti
@en
Silvia Stacchiotti
@es
Silvia Stacchiotti
@nl
prefLabel
Silvia Stacchiotti
@ast
Silvia Stacchiotti
@en
Silvia Stacchiotti
@es
Silvia Stacchiotti
@nl
P106
P1153
6506521747
P21
P214
5418153411841141700000
P31
P496
0000-0002-1742-8666
P735
P7859
viaf-5418153411841141700000